Natriuretic Peptide, C-Type

"Natriuretic Peptide, C-Type" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A PEPTIDE of 22 amino acids, derived mainly from cells of VASCULAR ENDOTHELIUM. It is also found in the BRAIN, major endocrine glands, and other tissues. It shares structural homology with ATRIAL NATRIURETIC FACTOR. It has vasorelaxant activity thus is important in the regulation of vascular tone and blood flow. Several high molecular weight forms containing the 22 amino acids have been identified.

Descriptor ID	D020098
MeSH Number(s)	D06.472.699.584.750 D12.644.548.585.750
Concept/Terms	Natriuretic Peptide, C-Type Natriuretic Peptide, C-Type Natriuretic Peptide, C Type Peptide, C-Type Natriuretic CNP-22 C-Type Natriuretic Peptide-22 C Type Natriuretic Peptide 22 Natriuretic Peptide-22, C-Type Peptide-22, C-Type Natriuretic C-Type Natriuretic Peptide C Type Natriuretic Peptide CNP-53 CNP-53 C-Type Natriuretic Peptide-53 C Type Natriuretic Peptide 53 Natriuretic Peptide-53, C-Type Peptide-53, C-Type Natriuretic

Below are MeSH descriptors whose meaning is more general than "Natriuretic Peptide, C-Type".

Chemicals and Drugs [D]
Hormones, Hormone Substitutes, and Hormone Antagonists [D06]
Hormones [D06.472]
Peptide Hormones [D06.472.699]
Natriuretic Peptides [D06.472.699.584]
Natriuretic Peptide, C-Type [D06.472.699.584.750]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Peptide Hormones [D12.644.548]
Natriuretic Peptides [D12.644.548.585]
Natriuretic Peptide, C-Type [D12.644.548.585.750]

Below are MeSH descriptors whose meaning is related to "Natriuretic Peptide, C-Type".

Below are MeSH descriptors whose meaning is more specific than "Natriuretic Peptide, C-Type".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Natriuretic Peptide, C-Type" by people in this website by year, and whether "Natriuretic Peptide, C-Type" was a major or minor topic of these publications.

Bar chart showing 5 publications over 5 distinct years, with a maximum of 1 publications in 2014 and 2020 and 2021 and 2022 and 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2014	1	0	1
2020	1	0	1
2021	1	0	1
2022	1	0	1
2024	0	1	1

Below are the most recent publications written about "Natriuretic Peptide, C-Type" by people in Profiles.

Qi Y, Chan ML, Mould DR, Larimore K, Fisheleva E, Cherukuri A, Day J, Savarirayan R, Irving M, Bacino CA, Hoover-Fong J, Ozono K, Mohnike K, Wilcox WR, Bober MB, Henshaw J. Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model. Clin Pharmacokinet. 2024 May; 63(5):707-719.

View in: PubMed
Rintz E, Wegrzyn G, Fujii T, Tomatsu S. Molecular Mechanism of Induction of Bone Growth by the C-Type Natriuretic Peptide. Int J Mol Sci. 2022 May 25; 23(11).

View in: PubMed
Savarirayan R, Tofts L, Irving M, Wilcox WR, Bacino CA, Hoover-Fong J, Font RU, Harmatz P, Rutsch F, Bober MB, Polgreen LE, Ginebreda I, Mohnike K, Charrow J, Hoernschemeyer D, Ozono K, Alanay Y, Arundel P, Kotani Y, Yasui N, White KK, Saal HM, Leiva-Gea A, Luna-Gonz?lez F, Mochizuki H, Basel D, Porco DM, Jayaram K, Fisheleva E, Huntsman-Labed A, Day JRS. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. Genet Med. 2021 12; 23(12):2443-2447.

View in: PubMed
Savarirayan R, Tofts L, Irving M, Wilcox W, Bacino CA, Hoover-Fong J, Ullot Font R, Harmatz P, Rutsch F, Bober MB, Polgreen LE, Ginebreda I, Mohnike K, Charrow J, Hoernschemeyer D, Ozono K, Alanay Y, Arundel P, Kagami S, Yasui N, White KK, Saal HM, Leiva-Gea A, Luna-Gonz?lez F, Mochizuki H, Basel D, Porco DM, Jayaram K, Fisheleva E, Huntsman-Labed A, Day J. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet. 2020 09 05; 396(10252):684-692.

View in: PubMed
Olney RC, Prickett TC, Espiner EA, Mackenzie WG, Duker AL, Ditro C, Zabel B, Hasegawa T, Kitoh H, Aylsworth AS, Bober MB. C-type natriuretic peptide plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia. J Clin Endocrinol Metab. 2015 Feb; 100(2):E355-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement